title: Effect of intensive glycaemic control on fibrinogen plasma concentrations in patients with Type II diabetes mellitus. Relation with beta-fibrinogen genotype.
abstract: Recent studies show that in diabetic subjects an increase of plasma fibrinogen concentration is associated with a high risk of cardiovascular complications. Environmental and genetic factors contribute to the plasma fibrinogen concentration. Several studies indicate a relation between the polymorphism in the 5' region of the beta-fibrinogen gene and plasma protein concentrations and in diabetes the possible influence of hyperglycaemia on fibrinogen is still debated. In this study we investigated these relations. Hind III polymorphism was evaluated by a polymerase chain reaction-technique. On the basis of the observed allelic combination of fibrinogen beta-gene polymorphism and the existence of poor metabolic control (glycated haemoglobin > or = 7.5%), 50 Type II diabetic patients were selected. They were divided into three groups according to their beta-gene polymorphism (alpha1alpha1: n = 20, alpha1alpha2: n = 15, alpha2alpha2: n = 15) and then intensive insulin therapy was started. After 3 months of intensive treatment, the improvement in glycaemic control was equivalent, in terms of glycated haemoglobin, in all the three groups. A fibrinogen reduction was observed in alpha1alpha2 and alpha2alpha2 but not in alpha1alpha1 subjects. These results underline a possible relation between fibrinogen genotypes and glycaemic control in determining plasma fibrinogen concentrations in diabetic patients.
authors.affiliation: Department of Internal Medicine, University of Udine, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Ceriello
authors.forename: F
authors.initials: F
authors.lastname: Mercuri
authors.forename: D
authors.initials: D
authors.lastname: Fabbro
authors.forename: R
authors.initials: R
authors.lastname: Giacomello
authors.forename: G
authors.initials: G
authors.lastname: Stel
authors.forename: C
authors.initials: C
authors.lastname: Taboga
authors.forename: L
authors.initials: L
authors.lastname: Tonutti
authors.forename: E
authors.initials: E
authors.lastname: Motz
authors.forename: G
authors.initials: G
authors.lastname: Damante
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D002097:C-Reactive Protein / Q000378:metabolism; D015247:Deoxyribonuclease HindIII; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D005340:Fibrinogen / Q000235:genetics* / Q000378:metabolism*; D005838:Genotype; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length
chemical_list: D001786:Blood Glucose; D002097:C-Reactive Protein; D015247:Deoxyribonuclease HindIII; D005340:Fibrinogen; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin